Image

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Exploring new treatment options for Triple-Negative Breast Cancer.

Recruiting
18 years and older
All
Phase 3
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study is looking at a drug called sacituzumab tirumotecan (Sac-TMT) to see if it helps treat triple-negative breast cancer (TNBC) alone or with another medication called pembrolizumab (MK-3475). TNBC is a type of breast cancer that doesn't have three common receptors found in other breast cancers, which makes it harder to treat. The study wants to know if patients live longer without the cancer spreading compared to standard chemotherapy treatment.

  • Participants may receive Sac-TMT alone or with pembrolizumab.
  • To join, participants cannot have had certain treatments before.
  • There are specific health criteria to meet before participating.

Key Points: The study might involve trying new treatments, which could have unknown benefits and risks. Participants need to meet specific health criteria to join. The study will help researchers learn more about treating TNBC.

Print
Study details
    Triple Negative Breast Neoplasms

NCT06841354

Merck Sharp & Dohme LLC

25 April 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Race
Ethnicity
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.